Payment overview · 2025
General Payments
$297.33
17 reported records · 10 companies
Healthcare provider profile · identity verified
Robert Barnes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SENATOBIA, MS · NPI 1720577380
Verified facts
What the public records show
CMS Open Payments records show Robert Barnes, MD received $297.33 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 362 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.25 | 27.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.27 | 18.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.75 | 14.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.96 | 6.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.78 | 6.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $16.96 | 5.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.49 | 5.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.87 | 5.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.71 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.29 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $297.33 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.84 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.27 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.29 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 158 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 362 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
180 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
362 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 729 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 380 | 115 |
| Mounjaro | Tirzepatide | 362 | 53 |
| Metformin Hcl Er | Metformin Hcl | 311 | 95 |
| Gabapentin | Gabapentin | 306 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 79 |
| Diclofenac Sodium | Diclofenac Sodium | 274 | 75 |
| Chlorthalidone | Chlorthalidone | 260 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 73 |
| Meloxicam | Meloxicam | 251 | 88 |
| Carvedilol | Carvedilol | 248 | 65 |
| Famotidine | Famotidine | 210 | 64 |
| Furosemide | Furosemide | 210 | 68 |
| Potassium Chloride | Potassium Chloride | 204 | 66 |
| Omeprazole | Omeprazole | 198 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 67 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 187 | 63 |
| Farxiga | Dapagliflozin Propanediol | 180 | 45 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 179 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 49 |
| Jardiance | Empagliflozin | 158 | 52 |
| Montelukast Sodium | Montelukast Sodium | 158 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 44 |
| Spironolactone | Spironolactone | 137 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 35 |
| Losartan Potassium | Losartan Potassium | 123 | 35 |
| Ozempic | Semaglutide | 123 | 37 |
| Telmisartan | Telmisartan | 122 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 38 |
| Ondansetron Odt | Ondansetron | 105 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 36 |
| Tramadol Hcl | Tramadol Hcl | 99 | 36 |
| Pregabalin | Pregabalin | 98 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 32 |
| Allopurinol | Allopurinol | 81 | 19 |
| Bupropion Xl | Bupropion Hcl | 80 | 19 |
| Trulicity | Dulaglutide | 78 | 21 |
| Aripiprazole | Aripiprazole | 75 | 22 |
| Lisinopril | Lisinopril | 74 | 22 |
| Eliquis | Apixaban | 73 | 23 |
| Metformin Hcl | Metformin Hcl | 72 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 18 |
| Torsemide | Torsemide | 71 | 16 |
| Trazodone Hcl | Trazodone Hcl | 67 | 23 |
| Prednisone | Prednisone | 66 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 20 |
| Buspirone Hcl | Buspirone Hcl | 65 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 21 |
| Methylprednisolone | Methylprednisolone | 63 | 52 |
| Sertraline Hcl | Sertraline Hcl | 63 | 23 |
| Ezetimibe | Ezetimibe | 62 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 16 |
| Azelastine Hcl | Azelastine Hcl | 60 | 17 |
| Clonazepam | Clonazepam | 55 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Glimepiride | Glimepiride | 53 | 17 |
| Mirtazapine | Mirtazapine | 53 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 51 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 19 |
| Rybelsus | Semaglutide | 50 | 12 |
| Alprazolam | Alprazolam | 49 | suppressed |
| Anastrozole | Anastrozole | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 40 |
| Methocarbamol | Methocarbamol | 46 | 17 |
| Nifedipine Er | Nifedipine | 46 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 12 |
| Finasteride | Finasteride | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Alendronate Sodium | Alendronate Sodium | 44 | 18 |
| Belsomra | Suvorexant | 40 | 15 |
| Dayvigo | Lemborexant | 40 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 18 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 16 |
| Promethazine Hcl | Promethazine Hcl | 29 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | 11 |
| Doxepin Hcl | Doxepin Hcl | 28 | 11 |
| Linzess | Linaclotide | 28 | 12 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Victoza 3-Pak | Liraglutide | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 12 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Clotrimazole | Clotrimazole | 17 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Mupirocin | Mupirocin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $297.33 · 17 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, Hillrom - Vest System Model 105 Home Care, JARDIANCE, LINZESS, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, Vest Therapy Und, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error